FDA Approves Lenacapavir (Yeztugo) as Twice-Yearly HIV Prevention Injection
FDA Approves Lenacapavir (Yeztugo) as Twice-Yearly HIV Prevention Injection On June 19, 2025, the Food and Drug Administration (FDA) approved lenacapavir, marketed as Yeztugo, as the first twice-yearly injection for pre-exposure prophylaxis (PrEP) to prevent HIV infection. Previously approved in 2012 under the name Sunlenca as a treatment for HIV in individuals who no longer responded to other medications, lenacapavir’s mechanism involves targeting a protective shell HIV needs to survive, disrupting its growth and spread. Unlike most HIV drugs that…